阿维替尼 (AC0010) 是一种不可逆的突变选择性 EGFR 抑制剂，可有效抑制非小细胞肺癌 (NSCLC) 中的 EGFR T790M 耐药突变。 Abivertinib 也是一种新型 BTK 抑制剂。
| Cas No. | 1557267-42-1 |
| 别名 | 艾维替尼,Abivertinib; AC0010 |
| Canonical SMILES | CN1CCN(C2=C(F)C=C(NC3=NC(OC4=CC(NC(C=C)=O)=CC=C4)=C(C=CN5)C5=N3)C=C2)CC1 |
| 分子式 | C26H26FN7O2 |
| 分子量 | 487.5 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:10): 0.9 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 文献引用 | |
| 产品描述 | Avitinib is a pyrrolopyrimidine-based, irreversible inhibitor of the epidermal growth factor receptor (EGFR). It is selective for EGFR-active and T790M mutations, exhibiting a 298-fold increase in potency compared with wild-type EGFR. In a xenograft model, oral administration of 500 mg/kg avitinib was shown to result in complete remission of tumors with EGFR-active and T790M mutations. |
m.cnreagent.com